Biontech Se ADR (BNTX) Stock Price, Quote & News

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 6131 9084

Fax: 49 6131 9084

Website: www.biontech.de

Address:

An der Goldgrube 12, Mainz, Germany

DonCorleone77 Aug. 20 at 11:54 AM

$MRNA $MRK $BNTX Leerink says cancer vaccine win should sustain Merck momentum into fall Leerink notes Merck (MRK) and Moderna (MRNA) announced the top-line recurrence-free survival and distant metastasis-free survival success of the Phase 3 INTerpath-001 study of INT plus pembrolizumab in completed resected Stage IIB to IV melanoma. With this "unexpected Phase 3 success" of intismeran autogene combined with pembrolizumab in adjuvant melanoma, the firm expects positive investor reaction that will sustain momentum for Merck into the fall. The result is also positive, in Leerink's view, for cancer vaccine-levered stocks, but this no longer BioNTech (BNTX) and the firm expects any BioNTech gains today to fade as investors absorb the poor read-through. The firm has an Outperform rating on Merck.

0 · Reply

GordoHLYK13 Aug. 20 at 10:09 AM

$BNTX $CAPR $IBRX $IGC $SLS “$MRNA could be an intriguing strategic beneficiary if $IGC’s IGC-AD1 Phase 2 data validate a new cannabinoid-based approach to Alzheimer’s agitation—potentially opening the door to broader CNS opportunities, partnerships, or acquisition interest around innovative treatments.”

0 · Reply

GordoHLYK13 Aug. 20 at 8:17 AM

$IGC $SLS $IBRX $CAPR $BNTX CALMA Phase 2 Alzheimer's trial is within just six randomizations of closing enrollment, setting up top-line data readout in Q4

0 · Reply

CarrieSpence437 Aug. 20 at 7:39 AM

$BNTX $LPLA $EIX $PBA $NMR BioNTech remains focused on oncology and vaccine development, LPL Financial benefits from advisor and asset growth, Edison International provides regulated utility exposure, Pembina Pipeline benefits from Canadian energy infrastructure, and NMR remains execution-dependent. I'm watching clinical milestones, market levels, power demand, energy volumes, and liquidity.

0 · Reply

SethHarling755 Aug. 20 at 7:02 AM

$BNTX $UPST $MCD $AMTM BioNTech advances oncology and immunotherapy programs, Upstart remains sensitive to consumer-credit conditions, McDonald's benefits from global restaurant demand, and AMTM remains execution-dependent. I'm watching clinical milestones, credit performance, same-store sales, contracts, and margins.

0 · Reply

JasonPhillips739 Aug. 20 at 6:50 AM

$IBIT $BNTX $MRK $STLA IBIT provides spot Bitcoin exposure, BioNTech remains focused on oncology and immunotherapy development, Merck benefits from diversified pharmaceutical demand, and Stellantis remains focused on EV transition and global auto profitability. I'm watching Bitcoin flows, clinical milestones, drug sales, vehicle volumes, and margins.

0 · Reply

TNNStockAnalysisNews Aug. 20 at 5:47 AM

Top Stock Gainers Today (August 19, 2026): $MRNA — Closed at $174.38, Up an Almost Unbelievable 176.97% $BNTX — Closed Near $111.55-$112.17, Up as Much as 22.9% $MRK — Trading Up to $152.20, Gaining as Much as 12.6% to a Record High $KC — Rising 10.6% on a Surprise Break-Even Quarter $NVAX — Climbing More Than 7% on Sector-Wide Vaccine Momentum https://truthsandnews.com/markets/top-stock-gainers-today-august-19-2026-moderna-explodes

0 · Reply

I_Value_Life Aug. 20 at 5:44 AM

$BNTX sold my last lot here, cutting my losses..

0 · Reply

eightytwentie Aug. 20 at 3:48 AM

$BNTX this is Biontech all year baby

0 · Reply

Bullish_Visions Aug. 20 at 3:42 AM

$MRVI $BNTX Best ticker heading into tomorrow PWCM! This Crypto play is setting up for a monster move, insanely small float and fits the theme! Make sure to put PWCM on ur watch bulls!

0 · Reply

Market Cap	23.45B
Revenue (ttm)	3.25B
Net Income (ttm)	-1.29B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39.59%
Debt to Equity Ratio	0.02

Volume	8,776,300
Avg Vol	1,094,116
Day's Range	N/A - N/A
Shares Out	252.88M
Stochastic %K	89%
Beta	1.27
Analysts	Strong Sell
Price Target	$123.94